Literature DB >> 2784376

Significance of lateral node dissection for advanced rectal carcinoma at or below the peritoneal reflection.

Y Moriya1, K Hojo, T Sawada, Y Koyama.   

Abstract

Two hundred thirty two patients with rectal cancer at or below the peritoneal reflection, who underwent extended systematic lymphadenectomy, especially lateral node dissection, were reviewed with respect to survival rate, degree of surgical technique, and mode of recurrence. On the basis of the extent of lateral node spread, two types of lateral node dissection were performed, consisting of preservation of internal iliac vessels (conventional) and en bloc excision of these vessels (extended). The overall disease-free five-year survival rate was 69.4 percent in all patients--75.8 percent for those who underwent extended resection and 67.4 percent for those who underwent conventional resection an excellent survival rate of 49 percent of patients with lateral node metastasis was obtained. The analysis was carried out with regard to prognostic factors such as number of node metastases, obesity index, mode of recurrence, etc. We would recommend that systemic lymphadenectomy with lateral node dissection be performed for advanced rectal cancer at or below the peritoneal reflection.

Entities:  

Mesh:

Year:  1989        PMID: 2784376     DOI: 10.1007/bf02553486

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  56 in total

1.  Improved outcome following preoperative radiochemotherapy: 40.5 Gy accelerated hyperfractionation and 5-fluorouracil suppositories for patients with carcinoma of the lower rectum.

Authors:  H Horie; H Kashiwagi; F Konishi; K Furuta; A Ozawa; K Kanazawa
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Laparoscopic lateral pelvic lymph node dissection is achievable and offers advantages as a minimally invasive surgery over the open approach.

Authors:  Kinuko Nagayoshi; Takashi Ueki; Tatsuya Manabe; Taiki Moriyama; Kosuke Yanai; Yoshinao Oda; Masao Tanaka
Journal:  Surg Endosc       Date:  2015-08-15       Impact factor: 4.584

Review 3.  Locally recurrent rectal cancer: surgical strategy.

Authors:  J P de Azevedo; R R Dozois; L L Gunderson
Journal:  World J Surg       Date:  1992 May-Jun       Impact factor: 3.352

4.  Laparoscopy-assisted low anterior resection with a prolapsing technique for low rectal cancer.

Authors:  Masaki Fukunaga; Akio Kidokoro; Toshiaki Iba; Kazuyoshi Sugiyama; Tetu Fukunaga; Kunihiko Nagakari; Masaru Suda; Seiichiro Yoshikawa
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

5.  Microscopic spread of low rectal cancer in regions of the mesorectum: detailed pathological assessment with whole-mount sections.

Authors:  Zhao Wang; Zongguang Zhou; Cun Wang; Gaoping Zhao; Youdai Chen; Hongkai Gao; Xuelian Zheng; Rong Wang; Daiyun Chen
Journal:  Int J Colorectal Dis       Date:  2004-12-22       Impact factor: 2.571

Review 6.  Chemoradiotherapy and adjuvant chemotherapy for rectal cancer.

Authors:  Toshiaki Watanabe
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

7.  Simplification of total mesorectal excision with colonic J-pouch anal anastomosis for middle and lower rectal cancer: one surgeon's experience.

Authors:  Masato Kusunoki; Yasuhiro Inoue; Hidenori Yanagi
Journal:  Surg Today       Date:  2008-07-31       Impact factor: 2.549

8.  Survival benefit of lateral lymph node dissection according to the region of involvement and the number of lateral lymph nodes involved.

Authors:  Shozo Yokoyama; Katsunari Takifuji; Tsukasa Hotta; Kenji Matsuda; Takashi Watanabe; Yasuyuki Mitani; Junji Ieda; Hiroki Yamaue
Journal:  Surg Today       Date:  2013-12-27       Impact factor: 2.549

9.  Lateral lymph node dissection for lower rectal cancer.

Authors:  T Nakamura; M Watanabe
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

10.  Lymph node metastases of prostatic adenocarcinoma in the mesorectum in patients with rectal cancer.

Authors:  In Ja Park; Hee Cheol Kim; Chang Sik Yu; Choung Soo Kim; Jung Sun Kim; Jin Cheon Kim
Journal:  Cancer Res Treat       Date:  2005-04-30       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.